Parithera, a Swiss and US startup spinning off from ETH Zürich and EPFL, developed in a collaboration with CSEM and CHUV, set itself the mission to revolutionize precision oncology. The company’s goal is to unravel tumor heterogeneity, improving treatment decisions in oncology. Powered by a specialized team, the board and a seasoned advisory board, the company is primed to drive its growth strategy forward.
Traditional tumor diagnostics, like tissue biopsies, do not offer longitudinal monitoring and often miss emerging tumor subclones, leading to suboptimal treatment decisions, while current tools for capturing circulating tumor cells (CTCs) or ctDNA yield low purity, limiting analysis accuracy. Parithera addresses this with their ExTrace tool, which achieves nearly 50% purity of CTCs, enabling single-cell resolution, to provide a more comprehensive view of tumor heterogeneity and unlock previously hidden information, while providing longitudinal monitoring capabilities. ExPlore, an AI analysis suite, provides simultaneous detection of clinically relevant biomarkers, including resistance markers and targets for multi-payload ADCs. ExPlore is open-source and enables analysis of any single-cell data – generated with any single-cell method.
